(Q38187489)

30 August 2017

title

Therapeutic targeting of the BAFF/APRIL axis in systemic lupus erythematosus (English)

1 reference

systemic lupus erythematosus

30 August 2017

main subject

0 references

author name string

William Stohl

series ordinal

1

1 reference

30 August 2017

language of work or name

English

0 references

publication date

13 February 2014

1 reference

Expert Opinion on Therapeutic Targets

30 August 2017

published in

1 reference

30 August 2017

volume

18

1 reference

30 August 2017

issue

4

1 reference

30 August 2017

page(s)

473-489

1 reference

An open study of B lymphocyte depletion in systemic lupus erythematosus

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

The BCMA gene, preferentially expressed during B lymphoid maturation, is bidirectionally transcribed

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

NF-AT activation induced by a CAML-interacting member of the tumor necrosis factor receptor superfamily

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B cell deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

Soluble BAFF levels inversely correlate with peripheral B cell numbers and the expression of BAFF receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

BAFF binds to the tumor necrosis factor receptor-like molecule B cell maturation antigen and is important for maintaining the peripheral B cell population

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

BAFF mediates survival of peripheral immature B lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

APRIL and TALL-I and receptors BCMA and TACI: system for regulating humoral immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

Identification of a receptor for BLyS demonstrates a crucial role in humoral immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

TACI is a TRAF-interacting receptor for TALL-1, a tumor necrosis factor family member involved in B cell regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

An Essential Role for BAFF in the Normal Development of B Cells Through a BCMA-Independent Pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

Local BLyS production by T follicular cells mediates retention of high affinity B cells during affinity maturation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

Cutting edge: the dependence of plasma cells and independence of memory B cells on BAFF and APRIL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

BLyS inhibition eliminates primary B cells but leaves natural and acquired humoral immunity intact

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

Regulation of the B cell receptor repertoire and self-reactivity by BAFF

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

Cellular competition independent of BAFF/B lymphocyte stimulator results in low frequency of an autoreactive clonotype in mature polyclonal B cell compartments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

Novel function of B cell-activating factor in the induction of IL-10-producing regulatory B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

Characterization of a new member of the TNF family expressed on antigen presenting cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

G-CSF-stimulated neutrophils are a prominent source of functional BLyS

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

Normal B cell homeostasis requires B cell activation factor production by radiation-resistant cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

The BAFF/APRIL system: emerging functions beyond B cell biology and autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

TGF-beta1 and IFN-gamma stimulate mouse macrophages to express BAFF via different signaling pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

Murine BAFF expression is up-regulated by estrogen and interferons: implications for sex bias in the development of autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

BAFF-induced NEMO-independent processing of NF-kappa B2 in maturing B cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

Alternative and classical NF-kappa B signaling retain autoreactive B cells in the splenic marginal zone and result in lupus-like disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

TRAF2 and TRAF3 signal adapters act cooperatively to control the maturation and survival signals delivered to B cells by the BAFF receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

Tumor necrosis factor receptor-associated factor 3 is a critical regulator of B cell homeostasis in secondary lymphoid organs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

The many faces of TRAF molecules in immune regulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

T cell costimulation by the TNF ligand BAFF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

BAFF augments certain Th1-associated inflammatory responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

BAFF promotes Th17 cells and aggravates experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

Increased CD4+Foxp3+ T Cells in BAFF-Transgenic Mice Suppress T Cell Effector Responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

Crystal structure of sTALL-1 reveals a virus-like assembly of TNF family ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

Crystal structure of the BAFF–BAFF-R complex and its implications for receptor activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

Ligand-receptor binding revealed by the TNF family member TALL-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

Crystal structure of extracellular human BAFF, a TNF family member that stimulates B lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

Structural basis of BLyS receptor recognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

TNF ligands: is TALL-1 a trimer or a virus-like cluster?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

TACI, unlike BAFF-R, is solely activated by oligomeric BAFF and APRIL to support survival of activated B cells and plasmablasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

Mutation of the BAFF furin cleavage site impairs B-cell homeostasis and antibody responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

No evidence that soluble TACI induces signalling via membrane-expressed BAFF and APRIL in myeloid cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

DeltaBAFF, an alternate splice isoform that regulates receptor binding and biopresentation of the B cell survival cytokine, BAFF

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

deltaBAFF, a splice isoform of BAFF, opposes full-length BAFF activity in vivo in transgenic mouse models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

Constitutive overexpression of BAFF in autoimmune-resistant mice drives only some aspects of systemic lupus erythematosus-like autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

BAFF and MyD88 signals promote a lupuslike disease independent of T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

BAFF overexpression and accelerated glomerular disease in mice with an incomplete genetic predisposition to systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

Paucity of clinical disease despite serological autoimmunity and kidney pathology in lupus-prone New Zealand mixed 2328 mice deficient in BAFF

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

B Cell and BAFF dependence of IFN-α-exaggerated disease in systemic lupus erythematosus-prone NZM 2328 mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

Correlation of the expression levels of BLyS and its receptors mRNA in patients with systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

Elevated B lymphocyte stimulator levels are associated with increased damage in an Irish systemic lupus erythematosus cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

Protein microarray analysis reveals BAFF-binding autoantibodies in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

Tumor necrosis factor (TNF) receptor superfamily member TACI is a high affinity receptor for TNF family members APRIL and BLyS

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

A soluble form of B cell maturation antigen, a receptor for the tumor necrosis factor family member APRIL, inhibits tumor cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

Biologically active APRIL is secreted following intracellular processing in the Golgi apparatus by furin convertase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

TACI and BAFF-R mediate isotype switching in B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

Heparan sulfate proteoglycan binding promotes APRIL-induced tumor cell proliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

Identification of proteoglycans as the APRIL-specific binding partners.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

An endogenous hybrid mRNA encodes TWE-PRIL, a functional cell surface TWEAK-APRIL fusion protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

B-lymphocyte stimulator/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B-cell maturation antigen-immunoglobulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

APRIL-deficient mice have normal immune system development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

Impaired IgA class switching in APRIL-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

APRIL modulates B and T cell immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

Dispensability of APRIL to the development of systemic lupus erythematosus in NZM 2328 mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

Selective APRIL blockade delays systemic lupus erythematosus in mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

A novel polymorphism of the human APRIL gene is associated with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

APRIL polymorphism and systemic lupus erythematosus (SLE) susceptibility

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

Genetic susceptibility to SLE: recent progress from GWAS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

Raised serum APRIL levels in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

Inverse association between circulating APRIL levels and serological and clinical disease activity in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

Identification of BLyS (B lymphocyte stimulator), a non-myelin-associated protein, as a functional ligand for Nogo-66 receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

The structure of the TNFRSF13C promoter enables differential expression of BAFF-R during B cell ontogeny and terminal differentiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

Regulated expression of BAFF-binding receptors during human B cell differentiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

Gene expression profiling reveals a highly specialized genetic program of plasma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

Gene expression profiling of plasma cells and plasmablasts: toward a better understanding of the late stages of B-cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

BAFF selectively enhances the survival of plasmablasts generated from human memory B cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

B cell maturation antigen, the receptor for a proliferation-inducing ligand and B cell-activating factor of the TNF family, induces antigen presentation in B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

Tonic B cell antigen receptor signals supply an NF-kappaB substrate for prosurvival BLyS signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

B-lymphocyte-induced maturation protein1 up-regulates the expression of B-cell maturation antigen in mouse plasma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

Mcl-1 is essential for the survival of plasma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

Selective activation of TACI by syndecan-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

BCMA is essential for the survival of long-lived bone marrow plasma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

B-cell maturation protein, which binds the tumor necrosis factor family members BAFF and APRIL, is dispensable for humoral immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

Deficiency in TNFRSF13B (TACI) expands T-follicular helper and germinal center B cells via increased ICOS-ligand expression but impairs plasma cell survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

Loss of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

The TACI receptor regulates T-cell-independent marginal zone B cell responses through innate activation-induced cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

CVID-associated TACI mutations affect autoreactive B cell selection and activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

The transmembrane activator TACI triggers immunoglobulin class switching by activating B cells through the adaptor MyD88

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

Mutations in TNFRSF13B encoding TACI are associated with common variable immunodeficiency in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

TACI is mutant in common variable immunodeficiency and IgA deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

TACI mutations and impaired B-cell function in subjects with CVID and healthy heterozygotes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

TACI is required for efficient plasma cell differentiation in response to T-independent type 2 antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

Deficient TACI expression on B lymphocytes of newborn mice leads to defective Ig secretion in response to BAFF or APRIL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

TACI deficiency impairs sustained Blimp-1 expression in B cells decreasing long-lived plasma cells in the bone marrow

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

Protective antiviral antibody responses in a mouse model of influenza virus infection require TACI

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

TNF family member B cell-activating factor (BAFF) receptor-dependent and -independent roles for BAFF in B cell physiology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

B cell-activating factor belonging to the TNF family acts through separate receptors to support B cell survival and T cell-independent antibody formation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

Mutational Analysis of Human BAFF Receptor TNFRSF13C (BAFF-R) in Patients with Common Variable Immunodeficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

B-cell activating factor receptor deficiency is associated with an adult-onset antibody deficiency syndrome in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

Development of systemic lupus erythematosus in NZM 2328 mice in the absence of any single BAFF receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

B cell maturation antigen deficiency exacerbates lymphoproliferation and autoimmunity in murine lupus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

Generation and characterization of LymphoStat‐B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

Effect of belimumab on vaccine antigen antibodies to influenza, pneumococcal, and tetanus vaccines in patients with systemic lupus erythematosus in the BLISS-76 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

Novel evidence-based systemic lupus erythematosus responder index

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

IgG anti-NR2 glutamate receptor autoantibodies from patients with systemic lupus erythematosus activate endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

Host-derived CD4+ T cells attenuate stem cell-mediated transfer of autoimmune arthritis in lethally irradiated C57BL/6.g7 mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

Rituximab and lupus: Good in real life, bad in controlled trials. comment on the article by Lu et al

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

B-cell targeted therapies in systemic lupus erythematosus: successes and challenges.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

B cell depletion therapy in systemic rheumatic diseases: different strokes for different folks?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

Protective and pathogenic roles for B cells during systemic autoimmunity in NZB/W F1 mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

Regulatory B cells (B10 cells) have a suppressive role in murine lupus: CD19 and B10 cell deficiency exacerbates systemic autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

B-cell targeted therapies in human autoimmune diseases: an updated perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

Mechanism of Action of Transmembrane Activator and Calcium Modulator Ligand Interactor-Ig in Murine Systemic Lupus Erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888415

10.1517/14728222.2014.888415

21 January 2018

Identifiers

DOI

1 reference

30 August 2017

1 reference